Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|June 30, 2025
Corrigendum: Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report seriesRegina Berkovich, Jonathan Calkwood, Heidi Crayton, et al.
International Journal of MS Care|June 3, 2016
Safety and Tolerability of Delayed-Release Dimethyl Fumarate Administered with Interferon Beta or Glatiramer Acetate in Relapsing-Remitting Multiple SclerosisJonathan Calkwood, Timothy Vollmer, Robert J Fox, et al.
Frontiers in Immunology|April 21, 2025
Switching to ublituximab from prior anti-CD20 monoclonal antibody therapy: a case report seriesRegina Berkovich, Jonathan Calkwood, Heidi Crayton, et al.
Expert Opinion on Drug Delivery|October 29, 2011
Results from the single-use autoinjector for self-administration of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis (MOSAIC) studySibyl Wray, Robert Armstrong, Craig Herrman, et al.
CNS Drugs|December 23, 2017
Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) StudyBianca Weinstock-Guttman, Jennie Medin, Nasreen Khan, et al.
Current Medical Research and Opinion|April 13, 2018
No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) studyRobert Zivadinov, Nasreen Khan, Jonathan R Korn, et al.
BMC Neurology|November 27, 2014
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trialJonathan Calkwood, Bruce Cree, Heidi Crayton, et al.
The American Journal of Gastroenterology|July 18, 2023
P038 Ozanimod First-Dose Cardiac Effects in Patients with Moderately to Severely Active Ulcerative Colitis and Relapsing Multiple SclerosisMillie Long, Raymond Cross, Jonathan Calkwood, et al.
Multiple Sclerosis and Related Disorders|March 11, 2018
Clinical outcomes in patients with relapsing-remitting multiple sclerosis who switch from natalizumab to delayed-release dimethyl fumarate: A multicenter retrospective observational study (STRATEGY)Stanley L Cohan, Harold Moses, Jonathan Calkwood, et al.
Pageof 1